Clarius Group LLC’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $808K | Sell |
6,583
-15
| -0.2% | -$1.82K | 0.05% | 146 |
|
|
2025
Q3 | $732K | Sell |
6,598
-2,155
| -25% | -$245K | 0.04% | 161 |
|
|
2025
Q2 | $970K | Buy |
8,753
+445
| +5% | +$47.4K | 0.06% | 151 |
|
|
2025
Q1 | $931K | Buy |
8,308
+1,460
| +21% | +$151K | 0.06% | 151 |
|
|
2024
Q4 | $633K | Sell |
6,848
-175
| -2% | -$15.8K | 0.04% | 180 |
|
|
2024
Q3 | $587K | Sell |
7,023
-278
| -4% | -$21.2K | 0.04% | 194 |
|
|
2024
Q2 | $501K | Sell |
7,301
-221
| -3% | -$14.7K | 0.04% | 214 |
|
|
2024
Q1 | $551K | Sell |
7,522
-2,319
| -24% | -$178K | 0.04% | 208 |
|
|
2023
Q4 | $797K | Buy |
9,841
+360
| +4% | +$28K | 0.07% | 156 |
|
|
2023
Q3 | $710K | Sell |
9,481
-3,559
| -27% | -$274K | 0.07% | 160 |
|
|
2023
Q2 | $1.01M | Buy |
13,040
+34
| +0.3% | +$2.71K | 0.08% | 141 |
|
|
2023
Q1 | $1.08M | Buy |
13,006
+1,098
| +9% | +$90.9K | 0.09% | 121 |
|
|
2022
Q4 | $1.02M | Buy |
11,908
+923
| +8% | +$73.1K | 0.09% | 132 |
|
|
2022
Q3 | $678K | Buy |
10,985
+4,664
| +74% | +$294K | 0.07% | 168 |
|
|
2022
Q2 | $391K | Sell |
6,321
-4,074
| -39% | -$252K | 0.04% | 264 |
|
|
2022
Q1 | $755K | Hold |
10,395
| – | – | 0.06% | 172 |
|
|
2021
Q4 | $755K | Buy |
10,395
+747
| +8% | +$51.5K | 0.06% | 172 |
|
|
2021
Q3 | $674K | Buy |
9,648
+344
| +4% | +$24.2K | 0.06% | 169 |
|
|
2021
Q2 | $641K | Buy |
9,304
+20
| +0.2% | +$1.33K | 0.06% | 174 |
|
|
2021
Q1 | $600K | Buy |
9,284
+3,573
| +63% | +$230K | 0.06% | 161 |
|
|
2020
Q4 | $333K | Sell |
5,711
-918
| -14% | -$55.4K | 0.04% | 240 |
|
|
2020
Q3 | $419K | Sell |
6,629
-4,162
| -39% | -$289K | 0.05% | 164 |
|
|
2020
Q2 | $830K | Buy |
10,791
+1,538
| +17% | +$118K | 0.12% | 94 |
|
|
2020
Q1 | $692K | Buy |
9,253
+1,171
| +14% | +$80.9K | 0.13% | 89 |
|
|
2019
Q4 | $518K | Buy |
8,082
+572
| +8% | +$37.3K | 0.08% | 123 |
|
|
2019
Q3 | $476K | Buy |
7,510
+1,140
| +18% | +$74.5K | 0.09% | 124 |
|
|
2019
Q2 | $430K | Buy |
6,370
+1,234
| +24% | +$81.2K | 0.09% | 122 |
|
|
2019
Q1 | $334K | Buy |
5,136
+1,703
| +50% | +$113K | 0.08% | 130 |
|
|
2018
Q4 | $215K | Buy |
+3,433
| New | +$240K | 0.08% | 112 |
|
|
2016
Q2 | – | Sell |
-2,505
| Closed | -$230K | – | 86 |
|
|
2016
Q1 | $230K | Sell |
2,505
-141
| -5% | -$12.7K | 0.13% | 73 |
|
|
2015
Q4 | $267K | Buy |
+2,646
| New | +$275K | 0.15% | 57 |
|
Other funds holding GILD
Clarius Group LLC's GILD Position: Q4 2025 in Review
Clarius Group LLC reduced its Gilead Sciences (GILD) stake by 0.23% in Q4 2025, selling an estimated $1.82K and leaving 6,583 shares worth $808K. The position accounts for 0.05% of the portfolio, ranked #146.
Clarius Group LLC first reported a position in GILD in Q4 2015 and has held it in 31 quarters since. The position peaked at $1.08M in Q1 2023. 2,216 funds tracked by Wall St. Rank hold GILD as of Q4 2025.
- Clarius Group LLC held 6,583 shares of Gilead Sciences worth $808K as of Q4 2025.
- Clarius Group LLC sold 15 Gilead Sciences shares in Q4 2025, an estimated $1.82K.
- Gilead Sciences made up 0.05% of Clarius Group LLC's portfolio in Q4 2025, its #146 holding.
- Clarius Group LLC first reported a position in Gilead Sciences in Q4 2015 and has held it in 31 quarters since.
- Clarius Group LLC's Gilead Sciences position peaked at $1.08M in Q1 2023.
- 2,216 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2025.
Based on Clarius Group LLC's 13F filing for Q4 2025, filed 14 Jan 2026.